Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.45 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | JAK1 | P23458 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 6/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6779716 | 0.79 | ALDH1A1 (0.46) | — | |
| SCHEMBL4837064 | 0.79 | DTYMK (0.47) | GPR119USP2SMN1; SMN2NAMPT | |
| SCHEMBL3355470 | 0.79 | KDM1A (0.42) | GPR119OPRD1OPRK1JAK2JAK1 | |
| Iodide SCHEMBL27209184 | 0.78 | DTYMK (0.47) | GPR119USP2SMN1; SMN2NAMPT | |
| SCHEMBL2018953 | 0.77 | GPR119 (0.50) | GPR119 | |
| SCHEMBL484477 | 0.76 | GPR119 (0.43) | GPR119JAK2JAK1NAMPT | |
| SCHEMBL8622484 | 0.75 | GPR119 (0.43) | GPR119OPRD1OPRK1USP2SMN1; SMN2 | |
| SCHEMBL3300328 | 0.75 | HPGD (0.46) | USP2SMN1; SMN2 | |
| SCHEMBL25133817 | 0.74 | GPR119 (0.53) | GPR119OPRD1OPRK1NAMPT | |
| SCHEMBL2349423 | 0.74 | USP2 (0.50) | GPR119USP2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6699870-B2 | Phthalazine compounds and therapeutic agents for erectile dysfunction | EISAI CO., LTD. (JP) | 2004-03-02 | — | — | US | disclosed |
| US-20030105074-A1 | Phthalazine compounds and therapeutic agents for erectile dysfunction | EISAI CO., LTD. | 2003-06-05 | — | — | US | disclosed |
| US-6498159-B1 | SUCH AS 4-((3-CHLORO-4-METHOXYBENZYL)AMINO)-1-((4-HYDROXY-4 -HYDROXYMETHYL)PIPERIDINO)-6-PHTHALAZINE CARBONITRILE | EISAI CO., LTD. (JP) | 2002-12-24 | — | — | US | disclosed |
| EP-1057819-A1 | PHTHALAZINE DERIVATIVES AND REMEDIES FOR ERECTILE DYSFUNCTION | Eisai Co., Ltd. (JP) | 2000-12-06 | — | — | EP | disclosed |
| EP-0632808-A1 | ANTIVIRAL PEPTIDES | Pfizer Limited (GB) | 1995-01-11 | — | — | EP | disclosed |
| WO-1993019059-A1 | ANTIVIRAL PEPTIDES | PFIZER LIMITED (GB) | 1993-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105074-A1 | Phthalazine compounds and therapeutic agents for erectile dysfunction | CLIC1, CBR1, CBR3 | GPR119 768/4885OPRD1 305/4885OPRK1 1043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.